COSM

+ Watchlist + Portfolio

Cosmos Health Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $0.19
52-Week Range: $0.16 – $1.32
Market Cap: $13.20M
P/E (TTM): —
EPS (TTM): -0.66
Dividend Yield: —

Advanced Metrics

Price/Book: 0.47
PEG Ratio: —
Return on Equity: -104.00%
Return on Assets: -18.42%
Gross Margin: 10.27%
Operating Margin: -15.41%
Profit Margin: -33.08%
Current Ratio: 1.05
Debt/Equity: 0.77
Total Debt: $15.98M
Free Cash Flow: $-10.00M
Revenue Growth: 28.80%
Earnings Growth: —
Enterprise Value: $35.48M

COSM Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$50.35M	$53.38M	$54.43M	$65.27M
Cost of Revenue	$44.39M	$49.03M	$50.12M	$57.38M
Gross Profit	$5.96M	$4.35M	$4.31M	$7.90M
Research & Development	—	$164.86K	$533.29K	$519.36K
Selling, General & Admin	$13.24M	$25.40M	$17.78M	$22.55M
Operating Expenses	$13.43M	$26.18M	$19.56M	$24.44M
Operating Income	-$7.47M	-$21.83M	-$15.25M	-$16.54M
EBITDA	-$8.90M	-$17.06M	-$13.92M	-$15.15M
Pretax Income	-$13.06M	-$18.54M	-$16.18M	-$19.14M
Income Tax	$775.05K	$0.00	$0.00	$0.00
Net Income	-$13.83M	-$18.54M	-$16.18M	-$19.14M
Diluted EPS	-33.16	-2.15	-1.17	-0.63
Diluted Shares	1.93M	11.97M	19.15M	30.29M

COSM Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$20.75M	$3.83M	$315.11K	$715.67K
Receivables	$27.21M	$21.71M	$15.88M	$22.56M
Inventory	$3.45M	$4.79M	$4.36M	$5.78M
Current Assets	$56.37M	$36.61M	$25.46M	$38.39M
Total Assets	$68.04M	$66.01M	$54.31M	$65.48M
Current Liabilities	$21.75M	$24.32M	$25.76M	$38.27M
Long-Term Debt	$2.86M	$3.04M	$1.56M	$5.85M
Total Debt	$12.03M	$12.42M	$11.82M	$19.97M
Total Liabilities	$28.38M	$29.97M	$29.78M	$47.05M
Retained Earnings	-$66.23M	-$91.64M	-$114.02M	-$133.17M
Shareholders' Equity	$39.66M	$36.04M	$24.53M	$18.42M
Working Capital	$34.62M	$12.29M	-$296.19K	$116.41K
Net Debt	—	$7.43M	$10.80M	$18.65M

COSM Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$14.87M	-$15.64M	-$7.72M	-$8.45M
Capital Expenditure	-$383.07K	-$9.17M	-$1.27M	-$152.82K
Free Cash Flow	-$15.25M	-$24.80M	-$8.98M	-$8.60M
Depreciation & Amortisation	$188.89K	$614.38K	$1.25M	$1.37M
Stock-Based Compensation	$24.40K	$577.93K	$1.69M	$2.31M
Investing Cash Flow	-$21.50K	-$13.76M	-$798.27K	-$2.01M
Financing Cash Flow	$35.05M	$12.69M	$5.05M	$14.06M
Share Repurchases	$0.00	-$100.45K	$0.00	—
Net Change in Cash	$20.16M	-$16.70M	-$3.47M	$3.59M

COSM Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$13.71M	$14.75M	$17.11M	$19.70M	$17.93M
Cost of Revenue	$11.66M	$13.58M	$14.51M	$17.62M	$16.55M
Gross Profit	$2.05M	$1.16M	$2.60M	$2.08M	$1.38M
Research & Development	$15.63K	$74.64K	$18.34K	$410.76K	$0.00
Selling, General & Admin	$2.55M	$3.38M	$4.03M	$12.60M	$3.22M
Operating Expenses	$2.88M	$3.81M	$4.42M	$13.32M	$3.57M
Operating Income	-$833.14K	-$2.65M	-$1.82M	-$11.24M	-$2.18M
EBITDA	-$310.55K	-$1.92M	-$4.10M	-$8.82M	-$1.64M
Pretax Income	-$818.10K	-$2.83M	-$5.35M	-$10.15M	-$2.81M
Income Tax	$0.00	$0.00	$0.00	$0.00	$0.00
Net Income	-$818.10K	-$2.83M	-$5.35M	-$10.15M	-$2.81M
Diluted EPS	-0.03	-0.10	-0.17	—	-0.06
Diluted Shares	26.04M	28.75M	30.63M	—	47.09M

COSM Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$742.88K	$655.50K	$889.44K	$715.67K	$514.70K
Receivables	$17.11M	$18.34M	$21.47M	$22.56M	$21.04M
Inventory	$4.74M	$5.11M	$5.68M	$5.78M	$5.65M
Current Assets	$27.84M	$30.56M	$38.10M	$38.39M	$36.89M
Total Assets	$57.19M	$61.84M	$69.49M	$65.48M	$62.37M
Current Liabilities	$26.59M	$31.17M	$38.53M	$38.27M	$34.08M
Long-Term Debt	$2.09M	$2.05M	$5.71M	$5.85M	$6.12M
Total Debt	$12.85M	$15.65M	$21.07M	$19.97M	$17.42M
Total Liabilities	$31.24M	$35.60M	$46.36M	$47.05M	$42.54M
Retained Earnings	-$114.84M	-$117.67M	-$123.02M	-$133.17M	-$135.97M
Shareholders' Equity	$25.95M	$26.23M	$23.13M	$18.42M	$19.83M
Working Capital	$1.26M	-$604.25K	-$430.03K	$116.41K	$2.81M
Net Debt	$11.43M	$14.31M	$19.52M	$18.65M	$16.24M

COSM Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$186.32K	-$1.21M	-$2.46M	-$4.60M	-$1.07M
Capital Expenditure	-$13.80K	-$118.56K	-$12.40K	-$8.05K	-$11.40K
Free Cash Flow	-$200.12K	-$1.33M	-$2.47M	-$4.60M	-$1.08M
Depreciation & Amortisation	$320.44K	$353.86K	$377.91K	$317.14K	$348.18K
Stock-Based Compensation	$556.61K	$603.02K	$570.60K	$582.01K	$535.79K
Investing Cash Flow	-$7.07K	$71.82K	-$1.01M	-$1.07M	-$708.96K
Financing Cash Flow	$560.86K	$1.60M	$7.19M	$4.70M	$347.63K
Share Repurchases	$0.00	—	—	—	$0.00
Net Change in Cash	$367.48K	$466.26K	$3.73M	-$967.23K	-$1.43M

Market Snapshot

About

Cosmos Health Inc. is a healthcare company focused on proprietary pharmaceuticals, nutraceuticals, and medical devices with operations primarily in Europe. Headquartered in Chicago, Illinois with European operations in Greece, the company develops, manufactures, and distributes healthcare products including the Sky Premium Life nutraceutical brand and Mediterranation branded products. Cosmos Health's pharmaceutical segment includes generic drugs and branded prescription medications. The company also has a medical device division and operates through partnerships with healthcare providers and distributors across European markets.